Neuroscientists to reveal new insights into Alzheimer’s
Dementia experts from UC San Francisco will join their peers from around the globe at the annual Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston from Oct. 24 to 27.
Presentations cover breakthroughs in therapies that clear amyloid – a hallmark of Alzheimer’s – and a symposium on patients with early Alzheimer’s symptoms who were treated with the anti-amyloid medication donanemab, which may be approved by the end of the year. Other topics include novel treatments, diagnostic blood biomarkers, amyloid-related imaging abnormalities (ARIA) and Medicare coverage.
This year’s ...











